史赛克公司-经济百科

本条目包含过多不是中文的内容，欢迎协助翻译。

若已有相当内容译为中文，可迳自去除本模板。

史赛克(stryker,又译：斯瑞克)

史赛克公司简介

史赛克公司是全球最大的骨科及医疗科技公司之一

史赛克公司是全球最大的骨科及医疗科技公司之一，总部设于美国密西根州的克拉马苏市，在全球有14个生产研发及销售分部，员工超过一万六千多人。产品涉及关节置换、创伤、颅面、脊柱、手术设备、神经外科、耳鼻喉、介入性疼痛管理、微创手术、导航手术、智能化手术室及网络通讯、生物科技、医用床、急救推床等。由于业绩良好，史赛克公司分别被美国著名的《财富》杂志及《BusinessWeek》评为财富500强公司及全美50大医疗公司之一。在2005年更被评为在医疗业界中最受景仰的公司。美国史赛克公司在纽约股票交易所上市。

美国史赛克公司亚太总部设于香港，支持史赛克公司在亚太地区多个国家的业务发展，包括大中华、澳洲、新西兰、韩国和东南亚地区；提供财务、人力资源、市场推广、信息管理及产品策略支持。美国史赛克公司亚太地区总裁为Mr.JIMCunnIFF。

StrykerCorporationNYSE:SYK,aglobalLEAderinorthopaEDIcmanufacture,isaKAlAMAzoo,MichiganbaseDMedicaltechnologyfirmengagedinthedevelOPMentandPRoductionofimplantsusedinjointreplaCEMent,trauma,craniomaxillofaCIAlandspinalsurgeries;BIologics;surgical,neurologic,ear,nose&throatandinterventionalpainequiPMent;endoscopic,surgicalNAVigation,commuNICationsanddigitalimagingsystems;aswellaspatienthandlingandemergencymedicalequipment.Presently,thecompanyisdividedintoseveraldiscreteoPErationalunits,EAChfunctioningaSAS EPArateentity:StrykerBiotech;StrykerCanada;StrykerCommunications;StrykerCraniomaxillofacial;StrykerDevelOPMent;StrykerEndoscopy;StrykerImaging;StrykerJapan;StrykerLatinAmerica;StrykERMedSurg;StrykerOrthopaedics;andStrykerSpine.

史赛克公司的名称由来

二十世纪三十年代末，美国密西根大学整形外科一位名叫HomerStryker的年轻好奇医生发现，某些医疗产品出现了短缺，不能满足他以及他的病人的需要。他没有接受当时医疗设备条件的限制，而是发挥他的创造性思维，发明了几种令整个医疗界都为之兴奋的新产品。

在密西根州的克拉马苏进行过实验后，史赛克医生继续针对整形外科问题设计出一些简单而又实用的解决方案，如史赛克翻转架，这是一张床，医疗专业人员可以用它来旋转不能移动的病人。到了1941年，市场对他的产品的需求非常大，因此史赛克医生创立了一家公司生产这些产品。他通过自己的实践，创造性发明了医疗史上使用最为广泛的产品之一：摆锯。摆锯使医生能够切开坚硬的物质，但又不会伤害里面的皮肤。

有了希望开发出更好的医疗产品以提高人们生活质量这一强烈的渴望做动力，史赛克医生继续用他的远见和创新精神激励着这家公司。1964年，史赛克医生退休，为了表彰他矢志不渝地提高整形外科病人生活质量，这家公司更名为史赛克公司。

History

TheOrthopediCFRaMECompany,precursorofStrykerCorporation,wasformedonFebruary20,1946byDr.HomerStryker,aKalamazoo,Michiganbasedorthopedist.Stryker,aninnovator,desireDToprovidepatientsmedicaltechnologiesthatwouldbothfostereffICIencyandobservedemonstratedneed.ACCOrdingly,hedevelopedtheTurningFrame—amobilehospitalbedthatallowedforrepositioningofinjurEDPatientswhileprovidiNGNecessarybodyimmobility,thecastcutter—acastcuttingapparatusthatremovedcastmaterialwithoutdamagingunderlyingtissues,andthewalkingheel,amongothers.In1964,thecompanynameunderwentrevISIonandwasofficiallychangedtoStrykerCorporation.

In1978,oneyearafterJohnBrownwasnamedPresidentandCEO,annualsalesreACHed$22.7million.In1979StrykermadeaninitialpublICOfferingofsTOCkandlateracquiredOsteonicsCorporation,enteringthereplacementhip,knee,andotherorthopaediCIMplantsmarket(Stryker).In1999annualsalesrEAChed$2.1billionandin2000StrykerwasincludedintheS&P500andtheForbesPlatinum400forthefirsttime.In2002salesreached$3.0billionandStrykerwaslistedintheFortune500forthefirsttime.

In2003StephenP.MacMillanjoinedStrykerasPresidentandCOO.In2005,annualsalesreached$4.9billionandJohnW.BrowntransitionedtothesingleroleofChairmanoftheBoardwhileSteveMacMillanbecamePresident&CEO.By2007,StrykersolditsPhysiotherapyAssociatesdivISIontoprivateequityfirmWaterStreetHealthcarePartnersfor$150million.

Asof2007-2008globalmarketoverviewoftopmedicaltechnologyfirms,StrykermaintainsanuMBer10locuswithtotalportfoliosalesinexcessof$6billion;thisfiguremarksanincreaseofapproximately20%overthepreviousperiod.Since1999thecompanyhassustainedcomparableratesofgrowth.Moreover,thefirmmaintains16%worldwideorthopaedicmarketshare;Strykerretainsmoreoftheorthopaedicmarketthananyotherofthenation’sforemostproducersinthesegment:DePuyOrthopaedics,ZimmerHoldings,Medtronic,Synthes,Smith&Nephew,andBiomet,amongothers.AnalystsremainspeculativewhethersimilarfigurescanbeachievedforthecurrentfiscalyearCITingregulatoryissuesandthecostlymitigationsoassociated.

Corporategovernance

Asof2008,membersoftheboardofdireCTOrsofStrykerCorporationare:

JohnW.Brown,Chairman
StephenP.MacMillan
HowardE.Cox,Jr.
DonaldM.Engelman,Ph.D.
LouiseL.Francesconi
WilliamU.Parfet
RondaE.Stryker

Recentacquisitions

InMarch2006StrykerabsorbedtheHaifra,IsraelbasedSightlineTechnologiesLtd.intoitsoperations.Siteline,amanufacturerofgastROIntestinalendoscopyapparatuses,propelledStrykerintotheflexibleendoscopymarket.InFebruaryofthesameyear,thefirmacquiredeTrauma.comCorp.,aprivatelyheldentityinvolvedinthedevelopmentofsoftwarefor"Picturearchivingandcommunicationsystem"(PACS);thecompanywasincorporatedintoStrykerEndoscopyBusiness.December2005,markedthecompany’sacquisition,bymerger,ofPlasmaSolCorp.for$17.5million.PlasmaSolproducestechnologiesallowingsterilizationofvariousMedSurgequipments.InAugust2004,Strykeracquired,for$120million,SpineCoreInc.,acompanyinvolvedinthedevelopmentofartificialspinaldisks.AbouttwoyearsprecedingthisDATe,inJuneof2002,thefirmacquiredtheSpinalImplantBusinessofSurgicalDynamicsInc.for$135million.Twoyearspriortothisdate,inAugustof2000,Strykeracquired,withstock,GUIdedTechnologies,Inc.,adeveloperandmanufacturerofopticallocalizerspurposedforuseinhealthcareandindustrial.In1998,StrykERPurchasedHowmedica,theorthopaedicdivisionofPFIzer,for$1.65billion.

Sponsorships

Strykermaintainsrelationshipswith,butnotlimitedto,thefollowingprofessionalandtradeorganizations:

TheAdvancedMedicalTechnologyAssociation(AdvaMed)
TheMedicalDevicesManufacturingAssociation(MDMA)
TheOrthopedicResearchandEducationFoundation(OREF)
NationalElectricalManufacturersAssociation(NEMA)
EuropeanFederationofNationalAssociationsofOrthopaediCSAndTraumatology(EFORT)
InternationalSocietyofOrthopaedicSurgeryandTraumatology(SICOT)
InternationalSocietyofArthroscopy,KneeSurgeryandOrthopaedicSportsMedicine(ISAKOS)
FoundationforOrthopaedicTrauma;SpeakingofWomen’sHealth
ArthritisFoundationandAmericanAcademyofOrthopaedicSurgeons(AAOS)
AssociationofPerioperativeRegisteredNurses(AORN)
AmericanOrthopaediCSOcietyforSportsMedicine(AOSSM)

Regulatorycontroversies

Sinceearly2007thecompanyhasreceivedthreelettersfromtheFederalDrugAdministrationCITingissuesincompliancy.Thefirstofwhich,aseven-pagecorrespondence,namedvariousissuesatanIrelandbasedmanufacturingfacilitysuchasuntimelyfixoffailuresandproceduralnoncomplianceinthetestingoffailedorotherwiseproblem-pronedevices.Thesecondofwhich,sentNovember2007,citesissuesatthefirm’sMahwah,N.J.facilityincludingpoorfixationofhipimplantcomponents,insomeinstancesrequiringmitigationbyrevisionsurgeries;exceededmicrobiallevelviolationsinthecLEAningaNDFinalpackagingareasofthesterileimplants;andfailuretoinstitutemeasuresinpreventionofrecurrenceoftheseandotherproblems.Thefinalwarningletter,sentApril2008,citesissuesatthefirm’sHopkinton,Mass.biotechnologyfacility.Again,issuesrelatetoqualityandnoncomplianceincludingfalsificationofdocumentsrelEVAnttothesellingofproductstohospitalswhicharetobesoldunderalimited,governmentmandatedbasis.Strykermaintainsthatemployeesinvolvedinthefalsificationofdocumentshavesincebeenterminated.

Infall2007,Strykeralongwiththerelatedcompanies:Biomet,ZimmerHoldings,DePuyOrthopaediCSAndSmith&Nephew,wereinvolvedinCIVilligationwiththeU.S.DepartmentofHealthandHumanServices,OfficeofInspectorGeneral.Thislitigationcalledforanetpayoutof$311millionasthegovernmentaldepartmentmaintainstheaforementionedcompaniesengagedinunlawfulkickbackstophysicianswhourgedhospitalstopurchasetheIRRespectiveproducts.Stryker,however,havingcooperatedearlyintheinvestigation,wasnotfined.

AsofFebruary2008adISPuteexistsbetweenStrykerCorp.andtheU.S.DepartmentofJustiCEConcerningasuBPoenalinkingthecompanytoaforementionedMISconductinsaleofproducts.Sincegovernmentalfilingoftheinjunction,Strykernotesthatithasproducedinexcessof300,000pagesofdocumentationincompliancewiththemandate.U.S.Governmentcounters,however,thatthedocumentationwasnotproperinscopeandformat.LawofficiaLSExpecttheinvestigationtopersistseveralmonths.